Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 3.4% – Time to Sell?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)’s share price traded down 3.4% on Wednesday . The company traded as low as $1.13 and last traded at $1.13. 37,714 shares changed hands during trading, a decline of 21% from the average daily volume of 47,994 shares. The stock had previously closed at $1.17.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Maxim Group assumed coverage on shares of Telomir Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $4.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Telomir Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.00.

Telomir Pharmaceuticals Stock Up 0.6%

The firm has a market cap of $77.51 million, a PE ratio of -1.26 and a beta of -0.25. The firm has a 50 day moving average of $1.15 and a 200 day moving average of $1.25.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its earnings results on Thursday, August 13th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.72).

Hedge Funds Weigh In On Telomir Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $359,000. Bank of New York Mellon Corp acquired a new stake in Telomir Pharmaceuticals in the second quarter valued at $66,000. World Investment Advisors purchased a new stake in Telomir Pharmaceuticals in the fourth quarter valued at approximately $47,000. Finally, OneDigital Investment Advisors LLC acquired a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth $29,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases and conditions associated with aging. The company’s research is centered on telomere biology, an area involving the protective structures at the ends of chromosomes that generally shorten as cells divide and age.

Telomir’s lead product candidate is TELOMIR-1, an orally administered small-molecule compound being investigated for its potential to address telomere shortening and support healthier cellular aging.